,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['bcsm', 'paradigm']
 glass ceiling are meant to be broken for paradigm-shift advancement db04 did it her2 addiction is not mandatory anymore for targeting successfully target her2 her2low is only a pragmatic (and imperfect) way for patient selection (daisy trial) #bcsm 
Head Breast Cancer Group; Head translational and immunotherapy research group; San Rafael Scientific Institute, Milan, Italy; #PrecisionImmunology